Diffuse Lung Disease & Interstitial Lung Disease

Jun 132011
 

Taveira-DaSilva reports an observational series of 19 women treated with sirolimus for lymphangioleiomyomatosis. Of 12 women with chylous pleural effusions, most had a large improvement or resolution in their effusions. Ann Intern Med 2011;154:797-805. In a randomized trial of 89 LAM patients published in NEJM March 2011, sirolimus reduced decline of lung function.

May 112011
 

Analyzing six minute walk distances from 822 people with idiopathic pulmonary fibrosis in an interferon-gamma-1b clinical trial, du Bois et al found those whose decline in six minute walk test distance was >50 meters in 24 weeks had a four-fold risk of death within one year. In everyone but those with the very worst functional status, 6MWT [… read more]

Feb 212011
 

Song et al retrospectively reviewed 461 cases of IPF (269 biopsy-proven) in Korea. More than a third of patients were hospitalized for respiratory deteriorations over a 2-year period. About half the deteriorations were attributed to acute exacerbations of IPF, with most of the rest attributed to infections (half the patients had BAL and/or ET aspirates [… read more]

Feb 182011
 

McCormack et al randomized 89 women with lymphangioleiomyomatosis to receive 2 mg rapamycin or placebo daily for 12 months, followed by 12 months of drug-free observation. Women receiving sirolimus had stable lung function on spirometry, fewer symptoms, fewer “respiratory events,” and better quality of life during the treatment period. This was tempered by GI, dermatologic, [… read more]